A new industry analysis argues that boosting patient referrals alone is not solving clinical trial recruitment slowdowns, because patients often stall after the referral before they reach screening and randomization. The piece emphasizes that the post-referral pathway—records transfer, eligibility determination, and decision support—remains the most failure-prone segment. The article frames the shift as urgent for companies facing the patent “supercliff,” where lost development time cannot be recovered. It suggests that technology should remove friction across the entire funnel rather than simply creating more referrals. For trial operations leaders, the message is a call to re-engineer workflows that happen after interest is generated, including how sites receive records and how eligibility determination is operationalized. Overall, the analysis positions “trial momentum” as a measurable operational objective tied to enrollment speed rather than marketing effort.